PYRROLO[1,2-A]BENZIMIDAZOLE-BASED QUINONES AND IMINOQUINONES - THE ROLE OF THE 3-SUBSTITUENT ON CYTOTOXICITY

被引:59
作者
SCHULZ, WG [1 ]
ISLAM, I [1 ]
SKIBO, EB [1 ]
机构
[1] ARIZONA STATE UNIV,DEPT CHEM & BIOCHEM,TEMPE,AZ 85287
关键词
D O I
10.1021/jm00001a016
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The influence of the 3-substituent on the cytotoxicity of the 6-aziridinylpyrrolo[1,2-a]benzimidazole quinones (PBIs), the 6-acetamidopyrrolo[1,2-a]benzimidazole quinones (APBIs), and the 6-acetamidopyrrolo[1,2-a]benzimidazole iminoquinones (imino-APBIs) was investigated by comparing LC(50) mean graphs consisting of 60 cancer lines. Increasing lipophilicity of the 3-substituent of PBIs and APBIs increased the cytotoxicity specifically in melanoma cell lines. The 3-substituent does not influence DNA cleavage by reduced PBIs, except for the S-carbamate derivative which shows enhanced cleavage. This property of the 3-carbamate is rationalized in terms of the PBI major groove binding model. The imino-APBIs show enhanced cytotoxicity in melanoma and renal cancer cell lines; the correlation coefficient for log LC(50) VS log lipophilicity is 0.8 to 0.9. COMPARE correlations revealed that the PBIs are activated by DT-diaphorase but that the APBIs and imino-APBIs are inactivated by this enzyme. Thus the latter two agents are cytotoxic only as quinones. It was noted that APBIs possess a similar cytotoxic profile to three anthracycline analogues. This observation suggests mechanistic similarities between both types of cytotoxic agents. Major conclusions of this study pertain to the design of agents displaying cytotoxicity specifically against melanoma and renal cancers and to the use of 60-cell line mean graphs and COMPARE in cancer drug QSAR.
引用
收藏
页码:109 / 118
页数:10
相关论文
共 18 条
[1]  
BEALL HD, 1994, CANCER RES, V54, P3196
[2]   A COMPARISON OF THE CYTOTOXIC AND PHYSICAL-PROPERTIES OF AZIRIDINYL QUINONE DERIVATIVES BASED ON THE PYRROLO[1,2-A]BENZIMIDAZOLE AND PYRROLO[1,2-A]INDOLE RING-SYSTEMS [J].
BORUAH, RC ;
SKIBO, EB .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (11) :1625-1631
[3]  
BOYD MR, 1989, PRINCIPLES PRACTICES, V3
[4]   E09 - A NOVEL BIOREDUCTIVE ALKYLATING INDOLOQUINONE WITH PREFERENTIAL SOLID TUMOR-ACTIVITY AND LACK OF BONE-MARROW TOXICITY IN PRECLINICAL MODELS [J].
HENDRIKS, HR ;
PIZAO, PE ;
BERGER, DP ;
KOOISTRA, KL ;
BIBBY, MC ;
BOVEN, E ;
DREEFVANDERMEULEN, HC ;
HENRAR, REC ;
FIEBIG, HH ;
DOUBLE, JA ;
HORNSTRA, HW ;
PINEDO, HM ;
WORKMAN, P ;
SCHWARTSMANN, G .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (06) :897-906
[5]  
HENRY D, 1979, J MED CHEM, V19, P619
[6]   SYNTHESIS AND PHYSICAL STUDIES OF AZAMITOSENE AND IMINOAZAMITOSENE REDUCTIVE ALKYLATING-AGENTS - IMINOQUINONE HYDROLYTIC STABILITY, SYN/ANTI-ISOMERIZATION, AND ELECTROCHEMISTRY [J].
ISLAM, I ;
SKIBO, EB .
JOURNAL OF ORGANIC CHEMISTRY, 1990, 55 (10) :3195-3205
[7]   STRUCTURE ACTIVITY STUDIES OF ANTITUMOR AGENTS BASED ON PYRROLO[1,2-A]BENZIMIDAZOLES - NEW REDUCTIVE ALKYLATING DNA CLEAVING AGENTS [J].
ISLAM, I ;
SKIBO, EB ;
DORR, RT ;
ALBERTS, DS .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (10) :2954-2961
[8]   DESIGN OF PYRIMIDO[4,5-G]QUINAZOLINE-BASED ANTHRAQUINONE MIMICS - STRUCTURE ACTIVITY RELATIONSHIP FOR QUINONE METHIDE FORMATION AND THE INFLUENCE OF INTERNAL HYDROGEN-BONDS ON QUINONE METHIDE FATE [J].
LEMUS, RH ;
SKIBO, EB .
JOURNAL OF ORGANIC CHEMISTRY, 1992, 57 (21) :5649-5660
[9]   DISPLAY AND ANALYSIS OF PATTERNS OF DIFFERENTIAL ACTIVITY OF DRUGS AGAINST HUMAN-TUMOR CELL-LINES - DEVELOPMENT OF MEAN GRAPH AND COMPARE ALGORITHM [J].
PAULL, KD ;
SHOEMAKER, RH ;
HODES, L ;
MONKS, A ;
SCUDIERO, DA ;
RUBINSTEIN, L ;
PLOWMAN, J ;
BOYD, MR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (14) :1088-1092
[10]  
PAULL KD, COMMUNICATION